Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies

NCT00666926 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT00666926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00666926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies
Lead sponsor
Verastem, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2005
Completion date
April 30, 2009
Enrollment
99 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasm, pancreatic neoplasm, prostatic neoplasm